We're joined by Martijn for an engaging discussion on VarmX's latest milestones & the wider biotech market.
In Q4 2025, VarmX signed a strategic collaboration with CSL to fully fund a global ph3 trial & pre-launch readiness for their lead asset VMX-C001 - a novel treatment to help restore blood coagulation in patients requiring urgent surgery or experiencing severe bleeding while on FXa DOACs.
Martijn shares insight on how the deal came about, what it could mean for patients and VarmX in future, and why CSL are the right partner to develop & deliver VMX-C001 globally.
